We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Plegridy (peginterferon beta-1a)

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Plegridy (peginterferon beta-1a)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Plegridy (peginterferon beta-1a) is a subcutaneous injectable therapy, in which interferon beta-1a is pegylated to extend its half-life to permit a less frequent dosing schedule.

    Plegridy is specifically indicated for relapsing forms of multiple sclerosis.

    Plegridy is supplied as a solution for subcutaneous administration. The recommended dosage of Plegridy is 125 micrograms injected subcutaneously every 14 days. Patients should start treatment with 63 micrograms on day 1. On day 15 (14 days later), the dose is increased to 94 micrograms, reaching the full dose of 125 micrograms on day 29 (after another 14 days). Patients should continue with the full dose (125 micrograms) every 14 days thereafter.

    Clinical Results

    FDA Approval

    The FDA approval of Plegridy was based on a randomized, double-blind, and placebo controlled, one-year study. The trial compared clinical and MRI outcomes at 48 weeks in patients who received Plegridy 125 micrograms (n=512) or placebo (n=500) subcutaneously once every 14 days. All subjects had a baseline Expanded Disability Status Scale (EDSS) score from 0 to 5, had experienced at least 2 relapses within the previous three years, and had experienced at least 1 relapse in the previous year. None of the subjects had progressive MS. Neurological evaluations were scheduled at baseline, every 12 weeks, and at the time of a suspected relapse. Brain MRI evaluations were scheduled at baseline, week 24, and week 48. The primary outcome was the annualized relapse rate over 1 year. The annualized relapse rate was 0.26 in the Plegridy arm and 0.40 in the placebo arm; relative reduction 36% (p=0.0007).

    Side Effects

    Adverse effects associated with the use of Plegridy may include, but are not limited to, the following:

    • injection site erythema
    • influenza-like illness
    • pyrexia
    • headache
    • myalgia
    • chills
    • injection site pain asthenia
    • injection site pruritus
    • arthralgia

    Mechanism of Action

    Plegridy (peginterferon beta-1a) is a subcutaneous injectable therapy, in which interferon beta-1a is pegylated to extend its half-life to permit a less frequent dosing schedule. Interferon-beta (IFN-beta) is a polypeptide, normally produced by fibroblasts, that has antiviral and antiproliferative effects. Binding of IFN-beta to its receptor induces a complex transcriptional response. In immune cells (the most likely target of IFN-beta's therapeutic effect in MS), IFN-beta reduces antigen presentation and T-cell proliferation, alters cytokine and matrix metalloproteinase (MMP) expression, and restores suppressor function. Therapeutic forms of IFN-beta can be produced in bacterial expression systems (IFN-beta1b) or in mammalian cells (IFN-beta1a). The exact mechanism by which Plegridy  exerts its effects in patients with multiple sclerosis is unknown.

    Additional Information

    For additional information regarding Plegridy or relapsing multiple sclerosis, please visit www.plegridy.com

    Approval Date: 2014-08-01
    Date Created: 2014-08-22 11:24:57
    Company Name: Biogen IDEC.
    Back to Listings

    Upcoming Events

    • 09Dec

      The Age of eSource: Modernizing Clinical Trials

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Patient-phsyician-consultation

      Giving Patients Back Their Voice in Clinical Trials

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing